BMY Receives EC Approval for Expanded Label of CAR T Cell Therapy Breyanzi
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 27 2025
0mins
Source: NASDAQ.COM
Bristol Myers Squibb Approval: The European Commission approved Breyanzi for treating adult patients with relapsed or refractory mantle cell lymphoma, marking its fourth approval in Europe for various lymphomas.
Clinical Trial Results: The approval is based on the TRANSCEND NHL 001 trial, showing an 82.7% response rate and 71.6% complete response rate among patients treated with Breyanzi.
Market Impact and Pipeline Expansion: Bristol Myers is focusing on expanding its drug pipeline due to challenges from generics affecting its legacy products, with recent share gains following positive news from Bayer's stroke prevention candidate.
Discontinuation of Librexia Study: Bristol Myers and Johnson & Johnson halted the Librexia study for milvexian after an interim analysis indicated it would not meet efficacy endpoints, but other studies for milvexian will continue as planned.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 230.180
Low
190.00
Averages
218.50
High
240.00
Current: 230.180
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Johnson & Johnson to Host Q2 Earnings Conference Call
- Earnings Call Schedule: Johnson & Johnson will host its Q2 earnings conference call on July 15 at 8:30 a.m. ET, led by CEO Joaquin Duato and the executive team, aimed at providing investors with a detailed analysis of financial performance and future outlook.
- Access Options: Investors can access the webcast and presentation materials via Johnson & Johnson's website, while telephone participants can dial in at 877-869-3847 for U.S. or 201-689-8261 for international calls, ensuring broad investor participation and transparency of information.
- Replay Availability: A replay of the call will be available approximately three hours after the conclusion, lasting until midnight on July 29, allowing those unable to attend live to access key insights, thereby enhancing communication between the company and its investors.
- Future Earnings Schedule: Johnson & Johnson has announced its next earnings call date for October 13, 2026, demonstrating the company's commitment to long-term financial transparency while providing investors with a clear timeline for planning.
See More
Jim Cramer Recommends Four Stocks for New Investors
- Diversification Strategy: Jim Cramer emphasized the need for diversification even as artificial intelligence dominates the market, ensuring long-term stability in investment portfolios to mitigate risks associated with single-theme investments.
- Stock Recommendations: Cramer recommended four stocks for new members to buy, including Alphabet, Amazon, Apple, and Nvidia, all of which demonstrate strong growth potential, particularly in their AI-related businesses.
- Market Outlook: Despite challenges faced by Meta and Microsoft, Cramer remains cautiously optimistic about their future performance, suggesting that these companies could achieve breakthroughs in the evolving AI landscape.
- Emerging Investment Opportunities: Stocks like Arm Holdings and Broadcom are showing strong performance, particularly in the data center and AI chip sectors, reflecting robust market demand for related technologies, making them worth watching for long-term growth potential.
See More
Analysis of Trump's Drug Pricing Policy Impact
- Drug Pricing Policy: Trump's Most-Favored-Nation policy aims to cap U.S. drug prices to match those of other developed nations, potentially impacting government programs like Medicare and leading to decreased sales and profits for drugmakers.
- Strong Revenue Outlook: Despite challenges from drug price negotiations, Johnson & Johnson expects to achieve $100.8 billion in revenue for 2023, reflecting a 7% year-over-year increase and demonstrating resilience in its diversified healthcare portfolio.
- New Product Development: Johnson & Johnson is seeking U.S. approval for its robotic-assisted surgery device, the Ottava system, which, despite competition, could benefit from the growing demand for minimally invasive procedures due to an aging population.
- Acquisition and Growth: Roche's acquisition of SAGA Diagnostics for up to $595 million aims to strengthen its position in the molecular residual disease testing market, which is one of the fastest-growing areas in diagnostics, potentially offsetting pressures from drug pricing policies.
See More
Trump's Drug Price Policy Could Impact Pharma Profits
- Drug Pricing Policy: Trump's Most-Favored-Nation policy aims to limit the prices the U.S. government pays for certain drugs, potentially triggering a domino effect on pharmaceutical companies' sales and profits in the world's largest pharmaceutical market.
- Strong Revenue Outlook: Despite challenges from drug price negotiations, Johnson & Johnson expects to achieve $100.8 billion in revenue this year, reflecting a 7% year-over-year increase and showcasing its resilience and adaptability in the diversified healthcare sector.
- Acquisition and Innovation: Roche's acquisition of SAGA Diagnostics, costing up to $595 million, aims to strengthen its position in the rapidly growing molecular residual disease testing market for cancer, which is expected to drive growth in its diagnostics business.
- Diversification Advantage: The diversified portfolios of Johnson & Johnson and Roche enable them to maintain competitiveness under Trump's drug pricing policies, particularly through ongoing innovation and investment in medical devices and diagnostics.
See More
Johnson & Johnson Acquires Gemtrack Technology Rights
- Technology Acquisition: Johnson & Johnson's DePuy Synthes has acquired rights to develop, manufacture, and commercialize Gemtrack technology from MinMax Medical, aiming to advance radiofrequency tracking in joint reconstruction surgeries and potentially set a new industry standard.
- Market Potential: The Gemtrack RF tracking technology is expected to eliminate the need for infrared cameras, reduce reliance on invasive anchors, and enable continuous, highly accurate real-time tracking, thereby enhancing surgical safety and efficiency.
- Application Scope: This technology can be applied to shoulder, hip, and knee procedures for navigation and robotic assistance, strengthening DePuy Synthes's competitive position in orthopedic surgery and addressing market demands for high-precision operations.
- Strategic Implications: By integrating Gemtrack technology, DePuy Synthes not only enhances the technological sophistication of its product line but also positions itself to lead in the future medical device market, driving long-term growth for the company.
See More
Declining Appeal of U.S. Treasuries Amid Rising Corporate Debt Interest
- Rising Treasury Yields: The yield on the two-year Treasury note has increased by 60 basis points this year, surpassing 4.00%, primarily due to the energy price surge from the Iran war, which is expected to compel the Federal Reserve to raise interest rates, thereby heightening investor concerns about Treasuries.
- Strong Corporate Debt Performance: Many blue-chip companies have outperformed Treasuries, with Apple's two-year bond yield narrowing to just 3 basis points above the Treasury yield, marking a record low spread and indicating a growing appeal of corporate debt over government bonds.
- Credit Rating Discrepancies: Microsoft and Johnson & Johnson are the only U.S. companies to hold AAA ratings from the three major agencies, while the U.S. government no longer has a AAA rating, reflecting that the risk of lending to corporations is now comparable to that of Treasuries, prompting investors to reassess risk-reward dynamics.
- Long-Term Investment Concerns: While corporate debt is viewed as lower risk, investors must consider long-term repayment capabilities, especially amid escalating global AI competition, which introduces uncertainties about companies' futures and their ability to meet debt obligations.
See More
Johnson & Johnson to Host Q2 Earnings Conference Call
- Earnings Call Schedule: Johnson & Johnson will host its Q2 earnings conference call on July 15 at 8:30 a.m. ET, led by CEO Joaquin Duato and the executive team, aimed at providing investors with a detailed analysis of financial performance and future outlook.
- Access Options: Investors can access the webcast and presentation materials via Johnson & Johnson's website, while telephone participants can dial in at 877-869-3847 for U.S. or 201-689-8261 for international calls, ensuring broad investor participation and transparency of information.
- Replay Availability: A replay of the call will be available approximately three hours after the conclusion, lasting until midnight on July 29, allowing those unable to attend live to access key insights, thereby enhancing communication between the company and its investors.
- Future Earnings Schedule: Johnson & Johnson has announced its next earnings call date for October 13, 2026, demonstrating the company's commitment to long-term financial transparency while providing investors with a clear timeline for planning.
See More
Jim Cramer Recommends Four Stocks for New Investors
- Diversification Strategy: Jim Cramer emphasized the need for diversification even as artificial intelligence dominates the market, ensuring long-term stability in investment portfolios to mitigate risks associated with single-theme investments.
- Stock Recommendations: Cramer recommended four stocks for new members to buy, including Alphabet, Amazon, Apple, and Nvidia, all of which demonstrate strong growth potential, particularly in their AI-related businesses.
- Market Outlook: Despite challenges faced by Meta and Microsoft, Cramer remains cautiously optimistic about their future performance, suggesting that these companies could achieve breakthroughs in the evolving AI landscape.
- Emerging Investment Opportunities: Stocks like Arm Holdings and Broadcom are showing strong performance, particularly in the data center and AI chip sectors, reflecting robust market demand for related technologies, making them worth watching for long-term growth potential.
See More
Analysis of Trump's Drug Pricing Policy Impact
- Drug Pricing Policy: Trump's Most-Favored-Nation policy aims to cap U.S. drug prices to match those of other developed nations, potentially impacting government programs like Medicare and leading to decreased sales and profits for drugmakers.
- Strong Revenue Outlook: Despite challenges from drug price negotiations, Johnson & Johnson expects to achieve $100.8 billion in revenue for 2023, reflecting a 7% year-over-year increase and demonstrating resilience in its diversified healthcare portfolio.
- New Product Development: Johnson & Johnson is seeking U.S. approval for its robotic-assisted surgery device, the Ottava system, which, despite competition, could benefit from the growing demand for minimally invasive procedures due to an aging population.
- Acquisition and Growth: Roche's acquisition of SAGA Diagnostics for up to $595 million aims to strengthen its position in the molecular residual disease testing market, which is one of the fastest-growing areas in diagnostics, potentially offsetting pressures from drug pricing policies.
See More
Trump's Drug Price Policy Could Impact Pharma Profits
- Drug Pricing Policy: Trump's Most-Favored-Nation policy aims to limit the prices the U.S. government pays for certain drugs, potentially triggering a domino effect on pharmaceutical companies' sales and profits in the world's largest pharmaceutical market.
- Strong Revenue Outlook: Despite challenges from drug price negotiations, Johnson & Johnson expects to achieve $100.8 billion in revenue this year, reflecting a 7% year-over-year increase and showcasing its resilience and adaptability in the diversified healthcare sector.
- Acquisition and Innovation: Roche's acquisition of SAGA Diagnostics, costing up to $595 million, aims to strengthen its position in the rapidly growing molecular residual disease testing market for cancer, which is expected to drive growth in its diagnostics business.
- Diversification Advantage: The diversified portfolios of Johnson & Johnson and Roche enable them to maintain competitiveness under Trump's drug pricing policies, particularly through ongoing innovation and investment in medical devices and diagnostics.
See More
Johnson & Johnson Acquires Gemtrack Technology Rights
- Technology Acquisition: Johnson & Johnson's DePuy Synthes has acquired rights to develop, manufacture, and commercialize Gemtrack technology from MinMax Medical, aiming to advance radiofrequency tracking in joint reconstruction surgeries and potentially set a new industry standard.
- Market Potential: The Gemtrack RF tracking technology is expected to eliminate the need for infrared cameras, reduce reliance on invasive anchors, and enable continuous, highly accurate real-time tracking, thereby enhancing surgical safety and efficiency.
- Application Scope: This technology can be applied to shoulder, hip, and knee procedures for navigation and robotic assistance, strengthening DePuy Synthes's competitive position in orthopedic surgery and addressing market demands for high-precision operations.
- Strategic Implications: By integrating Gemtrack technology, DePuy Synthes not only enhances the technological sophistication of its product line but also positions itself to lead in the future medical device market, driving long-term growth for the company.
See More
Declining Appeal of U.S. Treasuries Amid Rising Corporate Debt Interest
- Rising Treasury Yields: The yield on the two-year Treasury note has increased by 60 basis points this year, surpassing 4.00%, primarily due to the energy price surge from the Iran war, which is expected to compel the Federal Reserve to raise interest rates, thereby heightening investor concerns about Treasuries.
- Strong Corporate Debt Performance: Many blue-chip companies have outperformed Treasuries, with Apple's two-year bond yield narrowing to just 3 basis points above the Treasury yield, marking a record low spread and indicating a growing appeal of corporate debt over government bonds.
- Credit Rating Discrepancies: Microsoft and Johnson & Johnson are the only U.S. companies to hold AAA ratings from the three major agencies, while the U.S. government no longer has a AAA rating, reflecting that the risk of lending to corporations is now comparable to that of Treasuries, prompting investors to reassess risk-reward dynamics.
- Long-Term Investment Concerns: While corporate debt is viewed as lower risk, investors must consider long-term repayment capabilities, especially amid escalating global AI competition, which introduces uncertainties about companies' futures and their ability to meet debt obligations.
See More
